| Title: |
Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients. |
| Authors: |
Haebe, Sarah, Schuebbe, Gesa, Jurmeister, Philipp, von Bergwelt-Baildon, Michael, Westphalen, C. Benedikt, Lauer, Ulrich M., Kunz, Wolfgang G., Subklewe, Marion, Weigert, Oliver |
| Source: |
NPJ Precision Oncology; 1/25/2025, Vol. 9 Issue 1, p1-6, 6p |
| Subject Terms: |
MEDICAL sciences, IMMUNE checkpoint inhibitors, CHEMORADIOTHERAPY, PROGRAMMED death-ligand 1, NASOPHARYNX |
| Abstract: |
Rare cancers present significant challenges in diagnosis, treatment, and research, accounting for up to 25% of global cancer cases. Due to their rarity and atypical presentations, they are often misdiagnosed, resulting in late-stage detection and poor outcomes. Here, we describe a patient case with advanced metastatic nasopharynx NUT carcinoma, one of the rarest and most aggressive cancers. We conducted a comprehensive analysis of this patient's tumor, including Tumor Mutation Burden, Microsatellite Instability, and genetic profiling to explore further putative druggable targets. The tumor exhibited high PD-L1 expression and showed a notable response to immune checkpoint inhibitors when combined with platinum-based radio-chemotherapy. Our findings indicate that checkpoint inhibitors could play a critical role in treating NUT carcinoma, offering new therapeutic avenues and hope for patients with this challenging diagnosis. Whether PD-L1 expression may be a useful predictor of immune checkpoint inhibitor efficacy warrants further research. [ABSTRACT FROM AUTHOR] |
|
Copyright of NPJ Precision Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
